TL;DR
Prime made for students and young adults
- Fast, free delivery for dorm and study essentials
- Prime Video and Amazon Music included
- Member-only deals
The NIH and NASA announced the QuSAFE Challenge, which will seek quantum-enabled sensing approaches for measuring biological signals in laboratory models used in drug safety research. The challenge offers up to $7.1 million in prizes; submissions are scheduled to open Dec. 15, 2026, and close July 27, 2027.
NASA and the National Institutes of Health have announced the QuSAFE Challenge, a prize competition seeking quantum-enabled sensing methods to improve measurements in laboratory models used for drug safety research. The challenge offers up to $7.1 million in prizes, with submissions scheduled to open Dec. 15, 2026, and close July 27, 2027, according to NASA’s Oct. 29 announcement.
QuSAFE stands for Quantum-Enabled Predictive Preclinical NAMs for Toxicity and Safety. The challenge focuses on sensing in in vitro new approach methodologies, or NAMs, including organoids and microphysiological systems. These laboratory models can produce human-relevant information for drug development and safety evaluation, but the announcement says their biological signals can be difficult to measure with conventional assays and imaging.
NASA says existing approaches can be noisy, invasive, or insufficiently sensitive, making weak, early, or low-abundance signals harder to detect. Destructive measurements can also limit researchers’ ability to follow biological processes over time. The challenge is intended to draw on sensor-development research communities to address those measurement limits; NASA describes quantum-enabled sensing as having potential for high sensitivity, improved signal-to-noise performance, and nanoscale resolution.
The competition is a collaboration between NIH and NASA and supports NASA’s Biological and Physical Sciences Division, according to the agency. NASA lists a prize pool of up to $7.1 million and directs interested participants to QuSAFE’s challenge website for registration, rules, and eligibility information. The announcement does not specify how many awards will be made or how the total prize amount will be divided.
The challenge targets a practical limitation in preclinical research: laboratory models may capture human-relevant biology, but the value of those models depends in part on whether instruments can detect and track the signals they produce. More sensitive, less disruptive measurements could help researchers observe subtle biological changes and follow processes over time, if proposed tools perform as intended.
That aim has implications for both drug development and animal use. NASA describes in vitro NAMs as approaches that can support safety evaluation while reducing reliance on animals. The announcement does not claim that the competition will replace animal testing or establish that any particular sensor can do so. Rather, it seeks technologies that may improve the measurement capabilities of existing models.
The partnership also connects biomedical research needs with NASA’s interest in scientific capabilities for work beyond traditional laboratories. NASA says advances could benefit research in space and on Earth. The agency has not provided performance targets or outlined specific spaceflight applications, so the extent of those potential benefits remains to be determined.
Popular right now
KitchenAid Artisan 5-Qt Tilt-Head Stand Mixer – Almond Cream (KSM150PS)
Dyson Car+Boat Cordless Handheld Vacuum
De'Longhi Magnifica Evo Fully Automatic Espresso Machine with Manual Milk Frother, Silver
As an affiliate, we earn on qualifying purchases.
From In Vitro Models to Sensor Design
In vitro NAMs include laboratory systems such as organoids and microphysiological systems. They are used to study biological responses outside a whole animal and can contribute data to drug development and safety assessment. NASA’s announcement frames a central challenge not as the absence of such models, but as difficulty detecting some of their signals with current measurement methods.
Quantum-enabled sensing is the proposed technology focus. NASA says these approaches may offer high sensitivity, better signal-to-noise performance, and nanoscale resolution compared with conventional methods. Those are stated capabilities and motivations for the competition, not reported outcomes from the QuSAFE Challenge: the announcement does not identify selected teams, devices, test results, or validated improvements.
The agency’s Oct. 29, 2026, page describes the competition as a joint NIH–NASA effort and points to a separate website for participant information. Its stated schedule begins with submissions opening Dec. 15, 2026, followed by a closing date of July 27, 2027. Those dates are the announced timetable, not evidence that submissions have already opened.
Prize Rules and Results Await Detail
NASA’s announcement gives the challenge’s purpose, maximum prize pool, and submission dates, but it does not describe award categories, judging criteria, eligibility requirements, or technical benchmarks. Those details are directed to the QuSAFE website and should be checked in the official rules before potential participants make plans.
It is also not clear from the announcement which quantum-sensing technologies or biological models will be prioritized, how proposed systems will be tested, or what evidence will be required to show improved detection. No winning teams, prototype results, or independent performance assessments are reported. NASA’s descriptions of sensitivity and other advantages are the rationale for the competition, not proof that a submitted system will achieve them.
The announcement also does not set out how any resulting tools would be adopted in drug-development workflows, or whether they would change the use of animals in safety testing. Those outcomes would depend on technical performance, validation, and later research and regulatory decisions.
Submission Window Opens in December
The announced next milestone is the opening of submissions on Dec. 15, 2026. The deadline is July 27, 2027. Prospective participants can consult the QuSAFE Challenge website for registration, official rules, and eligibility details; NASA’s announcement does not provide a later timetable for judging or prize decisions.
As the competition proceeds, the key developments to watch will be the published rules, the kinds of sensing systems teams propose, and how organizers evaluate them in the specified laboratory models. Any claims about improved sensitivity, continuous monitoring, or research benefits will require results from the challenge and subsequent validation. NASA and NIH have not yet announced winners or demonstrated that a particular approach has met those goals.
Key Questions
What is the NIH–NASA QuSAFE Challenge?
It is a joint NIH–NASA prize challenge seeking quantum-enabled sensing approaches for in vitro models used in preclinical toxicity and drug-safety research.
How much prize money is available?
NASA lists up to $7.1 million in prizes. The announcement does not specify the number of awards or how the money will be allocated.
When can teams submit entries?
NASA says submissions are scheduled to open on Dec. 15, 2026, and close on July 27, 2027. The challenge website is the source for registration and official rules.
What research models does the challenge address?
The announcement names in vitro new approach methodologies, including organoids and microphysiological systems, which can generate data for drug development and safety evaluation.
Has the challenge shown that quantum sensors improve drug-safety testing?
No results are reported in NASA’s announcement. It presents potential advantages of quantum-enabled sensing as the basis for the competition; no winning technology or validated performance result has been announced.
Source: nasa.gov
